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Abstract
Background: In 2001 Brazilian citizens aged 40 or older were invited to participate in a nationwide population
screening program for diabetes. Capillary glucose screening tests and procedures for diagnostic confirmation
were offered through the national healthcare system, diagnostic priority being given according to the severity of
screening results. The objective of this study is to evaluate the initial impact of the program.
Methods: Positive testing was defined by a fasting capillary glucose ≥ 100 mg/dL or casual glucose ≥ 140 mg/dL.
All test results were tabulated locally and aggregate data by gender and clinical categories were sent to the
Ministry of Health. To analyze individual characteristics of screening tests performed, a stratified random sample
of 90,106 tests was drawn. To describe the actions taken for positive screenees, a random sub-sample of 4,906
positive screenees was actively followed up through home interviews.
Main outcome measures considered were the number of diabetes cases diagnosed and cost per case detected
and incorporated into healthcare.
Results: Of 22,069,905 screening tests performed, we estimate that 3,417,106 (95% CI 3.1 – 3.7 million) were
positive and that 346,168 (290,454 – 401,852) new cases were diagnosed (10.1% of positives), 319,157 (92.2%) of
these being incorporated into healthcare. The number of screening tests needed to detect one case of diabetes
was 64. As many cases of untreated but previously known diabetes were also linked to healthcare providers
during the Campaign, the estimated number needed screen to incorporate one case into the healthcare system
was 58. Total screening and diagnostic costs were US$ 26.19 million, the cost per diabetes case diagnosed being
US$ 76. Results were especially sensitive to proportion of individuals returning for diagnostic confirmation.
Conclusion:  This nationwide population-based screening program, conducted through primary healthcare
services, demonstrates the feasibility, within the context of an organized national healthcare system, of screening
campaigns for chronic diseases. Although overall costs were significant, cost per new case diagnosed was lower
than previously reported. However, cost-effectiveness analysis based on more clinically significant outcomes
needs to be conducted before this screening approach can be recommended in other settings.
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Background
Population, nutrition and epidemiological changes in the
last century have produced a health risk profile in which
chronic diseases such as diabetes mellitus account for a
growing proportion of the total disease burden [1]. In
2000 an estimated 171 million people, or 2.8% of the
world's population, were living with diabetes, Brazil being
one of the 10 countries with the highest number [2].
Diabetes is associated with high morbidity and mortality,
and substantial loss in quality of life. Associated direct
medical costs vary from 2.5% to 15% of total national
health expenditures, depending on prevalence and treat-
ment availability [3]. Annual deaths caused by diabetes in
Latin America and Caribbean have been estimated at
340,000 in 2000, representing a loss of 760,000 years of
productive life and total costs of U$ 65 billion [4]. In the
last decade, proportional mortality attributable to non-
communicable diseases rose significantly in Brazil, rank-
ing first in most states. Diabetes figures among the 10
major causes of mortality in the country [5] and current
best data suggests that the prevalence of undiagnosed dia-
betes is high [6].
The efficacy of various treatments in reducing diabetes
complications is well established [7-10]. Considering the
existence of a detectable pre-clinical period and availabil-
ity of acceptable and accurate screening tests, screening for
diabetes seems logical. Nonetheless, benefits of early
detection and treatment of undiagnosed diabetes and its
economic implications have yet to be clearly demon-
strated [11,12]. Thus, opportunistic screening of high-risk
individuals, as opposed to population-wide approaches,
has been recommended [13-15].
In this context, in 2001, the Brazilian Ministry of Health
proposed a National Plan for the Reorganization of Dia-
betes Mellitus and Hypertension Care [16]. As part of the
plan, a National Screening Campaign to Detect Diabetes
Mellitus was conducted. To our knowledge, this is the first
nationwide, population-based, campaign-style diabetes
screening program conducted. In Brazil, no specific diabe-
tes screening strategies were in place prior to this screening
campaign.
The objectives of this report are to briefly describe the pro-
gram, to evaluate its impact in terms of case detection and
incorporating detected cases into medical management,
to describe the total cost, and to estimate the cost per new
diabetes case diagnosed.
Methods
The main characteristics of the nationwide screening pro-
gram for diabetes have been previously described [17].
Briefly, all Brazilian citizens aged 40 or older were invited
via mass media mobilization strategies, to participate in
the National Campaign to Detect Diabetes Mellitus,
which was conducted by trained healthcare professionals
working in the publicly funded national healthcare sys-
tem between March 6th and April 7th, 2001. Screening was
performed using fingerstick capillary blood and portable
meters. At that time, there were approximately 40,000 pri-
mary healthcare units distributed in the country's 5,507
municipalities, most of the latter managing, to a varying
degree, their healthcare services locally. The number of
screening tests to be performed was determined assuming
that 75% of Brazilians aged 40 years or older estimated to
depend exclusively on public healthcare services would
participate [18].
At screening, individuals presented to primary healthcare
units, answered a brief questionnaire and had capillary
glucose measurement done. Age, ongoing treatment for
diabetes, and fasting condition were recorded on individ-
ual forms. Those who informed having had no food inges-
tion in the previous 4 hours were considered to be fasting.
Individuals with prior diabetes diagnosis or those who
informed to be receiving diabetes therapy were not
excluded from participation in the Campaign.
Referral for confirmatory diagnosis was based on the
severity of the screening result (Table 1). All tests results
were tabulated locally and aggregate data were sent to the
Ministry of Health.
In all, 95.3% of the country's municipalities participated,
with an estimated 31.1 million adults aged 40 or over
being targeted for screening. In fact, a total of 22.1 million
capillary glucose tests were performed.
To evaluate the initial impact of the screening program, a
stratified sampling process was used to select first a ran-
dom sample of 50 municipalities from all of Brazil's 5
regions, entrance probability being proportional to the
number of screening tests reported, and second, in each
municipality, one primary healthcare unit, again with
probability proportional to the number of tests reported.
For each of these units, individual screening forms
obtained from the municipality were randomly sampled
(random start with consecutive sampling thereafter) until
an adequate number had been obtained, this goal initially
set at 2,000 screenees and 200 positive screenees. In the
event that a selected primary healthcare unit or munici-
pality did not have 2,000 screenees or 200 positive scree-
nees, additional forms from a contiguous primary
healthcare unit or municipality (identified by an a priori
scheme) were randomly selected in order to achieve the
desired number.BMC Health Services Research 2008, 8:189 http://www.biomedcentral.com/1472-6963/8/189
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A total of 126,376 individual forms from all screenees in
the sampled primary healthcare units were thus selected.
From this sample, 12,799 records were excluded because
of missing data, illegibility, or improbable (< 2.2 and >
29.4 mmol/l) capillary glucose results. A final random
sample of 1,996 records in each municipality was
selected. In three municipalities, the number of records
obtained approximated the original number desired
(1,743; 1,833; and 1,895) to the point that additional
forms from adjacent municipalities were not obtained.
Two municipalities were excluded because more then
50% of the participants were recorded as having a positive
screening test, which was considered more likely due to
previous disposal of forms from negative individuals than
to chance. From the remaining 95,291 records, 5,185
(5.4%, 95% CI 4.8 – 6.1%) indicating treatment for dia-
betes prior to screening were also excluded. Final analysis
of data on screening forms thus considered 90,106 forms.
Home interviews were performed by trained professionals
using a standardized and piloted questionnaire 15 to 19
months after screening. From the 200 positive screenees
selected in each of the 48 municipalities, the first 100 were
selected for interview. The remaining 100, in their original
order of selection, served as a reserve in the event that
those selected could not be located or refused interview.
In total, 7,183 individuals were actively procured, and
4,991 interviewed. Among the 2,192 participants not
interviewed, 1,460 (67%) could not be located by the
address provided during the campaign, 271 (12%) had
moved, 202 (9%) were located but not found at home
after three visits, 115 (5%) refused interview and 144
(7%) were not interviewed for miscellaneous reasons. As
an additional 85 (1.7%) individuals had died by the time
the interview, 4,906 positive screenees were actually inter-
viewed.
Information obtained included socio-economic and life-
style characteristics; underlying medical conditions;
screening and confirmatory testing data and subsequent
healthcare services received.
Data on diagnostic confirmation and subsequent health
care from this sub-sample of positive screenees were
extrapolated to estimate the number of cases of diabetes
detected and the number of cases actually incorporated
into the healthcare system overall as a result of the nation-
wide screening program. The number of individuals
needed to screen to detect one case of diabetes and to
incorporate one case into health care were also estimated.
Data was analysed using EpiInfo v.6.04d and SAS for Win-
dows v.8 [19]. Confidence intervals for estimates derived
from the sub-sample of 4,906 positive screenees inter-
viewed in the follow-up study were estimated using
STATA v.8 [20], with region being the stratification varia-
ble and municipal primary health care unit the cluster.
The Ministry of Health provided information on direct
costs of the screening program at the national level, con-
sidering costs for mobilization and mass media advertis-
ing, purchase and distribution of screening test kits,
training of healthcare workers, and overall screening pro-
gram management.
The screening campaign was planned and conducted by
personnel already working for the healthcare system.
Considering opportunity costs associated with this cam-
paign, labor costs were estimated considering the costs for
Table 1: Classification of screening test results and recommendations made to individuals who participated in the National Campaign 
to Detect Diabetes Mellitus
Categoriesa Recommendation
Fasting capillary glucoseb (mmol/l) < 5.6 Normal Repeat test in 3 years
5.6 to 6.0 High normalc Schedule future appointment
6.1 to 6.9 Borderlinec Schedule future appointment
7.0 to 11.1 Altered Order fasting serum glucose and recommend return medical 
appointment
11.1 to 14.9 Diabetes likely Order fasting serum glucose and schedule clinical appointment
≥ 15.0 Diabetes very likely Immediate consultation with physician
Non-fasting capillary glucose (mmol/l) < 7.8 Normal Repeat test in 3 years
7.8 to 11.0 Borderline Schedule future appointment
11.1 to 14.9 Diabetes likely Order fasting serum glucose and schedule clinical appointment
≥ 15.0 Diabetes very likely Immediate consultation with physician.
Brazil, 2001.
a All screening results not classified as normal were considered positive.
b Fasting was defined as absence of food ingestion 4 hours prior to capillary glucose test.
c These subcategories were developed for the purpose of this study, having been treated as a single category (borderline) during the program 
implementation.BMC Health Services Research 2008, 8:189 http://www.biomedcentral.com/1472-6963/8/189
Page 4 of 10
(page number not for citation purposes)
individuals involved with planning and implementation
of the campaign in the National, State, Municipal, and
healthcare unit levels. Labor costs were estimated consid-
ering time allocation, professional category and respective
salary ranges, and number of professionals involved in
each of these levels. In the National level, 6 nurses and 4
medical doctors were working full time during 6 months
(average monthly wage US$ 1,362 for nurse and US$
1,915 for medical doctor) in planning and coordination
of the screening campaign. In average 1 nurse was work-
ing full time during 2 months in all the 26 states and Fed-
eral District in planning and coordination in the State
level (average monthly wage US$ 1,362). In all of the
5,301 municipalities participating in the screening cam-
paign, 1 professional with a bachelor or higher degree was
working during 2 months (average monthly wage US$
1,064) in planning and coordination activities in the
Municipal level. Time allocated by this professional to
screening campaign activities was estimated as a function
of the size of the municipality (full time in municipalities
with population ≥ 500,000; half-time in municipalities ≥
100,000 but <500,000; 25% in municipalities ≥ 50,000
but <100,000; and 10% in municipalities <100,000 pop-
ulation). One professional with a bachelor or higher
degree was responsible for supervisory activities at the pri-
mary healthcare unit where capillary glucose testing was
conducted. It was estimated that one such professional
would have allocated in average 8 hours per week in each
one of the 40,000 primary healthcare unit in the country
during the campaign (average monthly wage US$ 1,064).
In addition, community health agents were responsible
for conducting the testing (average monthly wage US$
269). It was estimated an average of 5 minutes per capil-
lary glucose test performed to instruct campaign partici-
pants to answer the questionnaire and perform the
testing, totaling 110,349,525 minutes or 1,839,159 hours
of work of these professionals in the local level
(22,069,905 tests performed * 5 minutes).
As confirmatory diagnosis consumes additional resources,
these costs were estimated for individuals who tested pos-
itive during the screening Campaign and reported having
returned for diagnostic confirmation (37.1%). These costs
included the costs of a confirmatory fasting plasma glu-
cose test and two additional physician visits for each indi-
vidual. For confirmation through the national healthcare
system, reimbursement values of US$ 0.79 for the glucose
test and US$ 1.09 for each physician visit were used to
estimate these costs [21]. Confirmatory diagnosis through
the private sector was estimated considering reference
reimbursement values from the Brazilian Medical Associ-
ation [22], these being US$ 1.49 for a fasting plasma glu-
cose test and US$ 5.32 for each physician visit.
Professionals who interviewed and screened participants
provide regular services at the primary healthcare units
and are paid at the municipal level. A questionnaire was
sent to a convenience sample of 14 municipalities selected
for their known strong engagement in the screening pro-
gram in order to evaluate the amount of costs incurred at
the local level during the nationwide screening program.
Direct municipal costs such as additional costs with
media, logistics and social mobilization, were estimated
as an additional proportion of total national costs.
This analysis considers the public healthcare system per-
spective since the costs of the nationwide screening pro-
gram are paid by this system. Time horizon considered
was 1 year and no costs or benefits were discounted.
All costs are presented in US Dollars, considering the
exchange rate of the Brazilian Real (R$) to the US Dollars
(US$) in December 2001 (1 US$ = 2.35 R$). To allow for
international comparison, results are also presented in
international dollars (Int$) considering the purchasing
power parity exchange rates in 2001 (1 Int$ = R$ 0.59), as
recommended by the WHO [23]. For sensitivity analyses,
based on results of the convenience sample, we estimated
that additional local costs during the nationwide screen-
ing program could have ranged from 10–25% of the total
costs dispensed by the national level.
A decision analytic model was used to estimate cost per
new diabetes case diagnosed as a result of the nationwide
screening program. Screening campaign was compared to
no screening. Costs per case were obtained dividing total
costs by the estimated number of cases diagnosed and by
the estimated number of cases incorporated into health
care.
We estimated the impact of variation in characteristics of
the screening program on the estimated cost per diabetes
case diagnosed through one-way sensitivity analysis.
Characteristics included proportion of individuals in a
fasting state when screened, proportion of individuals
with known diabetes among those screened, proportion
of positive screenees returning for confirmatory diagnosis,
and proportion of confirmatory testing done at public vs.
private providers. Additional local costs and a range of
varying labor costs during screening was also included in
sensitivity analysis. Base case scenario estimates and
ranges for each parameter included in sensitivity analysis
are presented in Table 2.
This study was carried out in accordance with the Declara-
tion of Helsinki as revised in 2000 [24]. The project was
approved by the Ethics Committee of the Universidade
Federal do Rio Grande do Sul. Written informed consent
was obtained prior to interview.BMC Health Services Research 2008, 8:189 http://www.biomedcentral.com/1472-6963/8/189
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Ethical Approval
The study was approved by the ethics committee of the
Federal University of Rio Grande do Sul, Brazil.
Results
Evaluation of the 90,106 screening forms revealed 16.4%
of screening exams to be positive.
Of the sample of 4,906 positive screenees interviewed,
56.9% were women, 47.3% were aged 60 and older, and
81.2% had less than a complete primary school educa-
tion. Although interviews were performed only for indi-
viduals not reporting treatment for diabetes at screening,
surprisingly, 786 (16%, 95% CI 14 – 18.1%) of those
interviewed reported having known diabetes prior to
screening. Additionally, 394 individuals (8%, 95% CI 5.8
– 10.2%) reported not remembering having participated
in the screening program at interview, approximately 1 1/
2 years afterwards. Of the remaining 3,726 individuals,
1,821 (48.9%, 95% CI 45.1 – 52.8%) informed that they
had returned for confirmatory diagnostic testing. This pro-
portion increased notably with increasing capillary glu-
cose value at screening (See Additional file 1).
The most frequent test used for diagnostic confirmation
was fasting venous glucose (1,399, 76.8%), followed by
fasting capillary glucose (310, 17%). Of these tests, 1,282
(70.4%) were publicly financed, 275 (15.1%) being cov-
ered by medical insurance and 239 (13.1%) paid for out-
of-pocket. The average time elapsed from screening to
confirmatory testing was 3 months. Medical consultation
for diagnostic confirmation followed testing in 371
(79%) of these cases; the time elapsed from confirmatory
testing to consultation was less than 8 days for half of the
patients, and ≤ 20 days for 75%. Of the medical visits, 265
(71.3%) were to public providers; with 212 (57.5%)
being at a primary healthcare unit.
The proportion of screen positives confirming a diagnosis
of diabetes varied according to screening result, from
1.6% (95% CI 0.9 – 2.8%) for those with a screening fast-
ing glucose of 5.6–6.1 mmol/l to 59.7% (95% CI 52.7 –
66.4%) for those with a screening glucose ≥ 15.0 mmol/l)
(See Additional file 1). In the sample analysed, 28 individ-
uals had diabetes diagnosis established at screening, and
469 at return visit by confirmatory test. Thus, the total
number of newly diagnosed diabetes cases in the sample
was 497, of whom 458 (92.2%) reported to be receiving
medical treatment at a healthcare service when inter-
viewed. Of those diagnosed, 210 (42.3%) were aged 60
years and older, and 403 (81.1%) had less than a com-
plete primary education. Self-reported data on weight and
height indicated overweight (BMI ≥ 25 kg/m2) in 294
(59.2%) and low-weight (BMI <18.5 kg/m2) in 113
(22.7%) of these newly diagnosed diabetes cases. In addi-
tion, 41 (8.8%) of the individuals who underwent con-
firmatory testing reported a result characterized by the
physician as not diabetes but "sugar intolerance" (thus
likely being diagnosed with impaired glucose tolerance or
impaired fasting glucose).
Table 2: Parameters considered in base case analysis and range for selected parameter estimates included in sensitivity analysis
Parameters Base Case Estimate Range
Proportion of population ≥ 40 years who participated in the screening program 73% -
Percentage of tests in screenees who reported to be under treatment for diabetes prior to 
screening
5.4% 4.8 – 6.1a
Percentage of subjects in fasting state when screenedb 46.7% 30 – 50%c
Percentage of positive screening testsd 16.4% -
Percentage of positive screenees who reported having diabetes diagnosis prior to the screening 
programe
16% 14 – 18.1%a
Percentage of positive screenees who returned for confirmatory testing 37.1% 0 – 100%c
Percentage of positive screenees who were diagnosed as having diabetes mellitus 10.1% -
Percentage of positive screenees diagnosed with diabetes and incorporated into the healthcare 
system
9.4% -
Additional local costs 0% 10 – 25%f
Estimated labor costs US$ 5.99 million US$ 4.65 – 8.98 million
Percentage of positive screenees who returned for confirmatory testing in the public system 
(as opposed to the private health sector)
100% 75 – 25%c
National Campaign to Detect Diabetes Mellitus. Brazil, 2001.
a Range corresponds to the 95% confidence interval of each estimate from the probabilistic sample.
b Fasting was defined as absence of food ingestion 4 hours prior to capillary glucose test.
c Range corresponds to an arbitrary estimate of the authors.
d Fasting glucose ≥ 5.6 mmol/l or a casual glucose ≥ 7.8 mmol/l.
e These subjects knew their previous diabetes diagnosis; however, they had not provided that information when asked about it during screening 
program.
f Range expressed as an additional percentage of national costs.BMC Health Services Research 2008, 8:189 http://www.biomedcentral.com/1472-6963/8/189
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Among the 786 individuals who participated in the
screening program but at interview reported diabetes diag-
nosis prior to screening, 355 (45.2%) were not receiving
medical care for diabetes prior to screening. Of these, 93
(26.2%) reported diabetes diagnosis confirmation after
screening and 88 (24.8%) reported to be receiving medi-
cal care for diabetes at interview.
Figure 1 outlines our estimate that 346,168 (95% CI
290,454 – 401,852) new diabetes cases were diagnosed,
of which 319,157 (95% CI 303,097 – 329,409) were
incorporated into healthcare. Thus, the number of screen-
ing tests needed to detect one new case of diabetes was 64
(95% CI 55 – 76). As an additional 61,293 (95% CI
44,866 – 77,739) individuals with previous diabetes diag-
Population estimates for the initial impact of the National Campaign to Detect Diabetes Mellitus Figure 1
Population estimates for the initial impact of the National Campaign to Detect Diabetes Mellitus. Brazil, 2001.
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nosis but not receiving medical assistance prior to screen-
ing also reported linking to medical care, a total of
380,450 (95% CI 322,917 – 437,731) cases of diabetes
were incorporated into the healthcare system as a result of
the screening program. Given this additional incorpora-
tion of prevalent but untreated cases, the number of tests
needed to incorporate one new case into the health sys-
tem was 58 (95% CI 50 – 68).
Total direct program costs dispensed at the national level
for screening were US$ 22,423,155 (Int$ 89,312,567).
Purchase of diagnostic material, including reagent strips
and glycometers, was the largest cost item in the nation-
wide screening program – US$ 13.19 million. Costs of
reagents and glycometers were US$0.42 per target individ-
ual to be screened ($13.19 million/31.1 million popula-
tion). Costs of personnel involved in planning and
implementing screening campaign were estimated at US$
5,988,783 (Int$ 23,853,627).
Total mobilization costs were US$ 3.11 million. Mobiliza-
tion costs considered were: elaboration of a media plan;
media time in radio, television, newspaper and billboard
announcements used to publicize screening days; and
printed material used during the Campaign (posters,
booklets, forms etc). Total training and program manage-
ment costs were US$ 136,499. Training on the use of cap-
illary glycometers was provided by the manufacturer as
part of the purchase contract.
Confirmatory diagnostic costs consumed an additional
US$ 3.75 million, as an estimated 1.26 million individu-
als returned for diagnostic confirmation at an estimated
cost of US$ 2.97 per person. Total cost for the screening
(US$ 22.4 million) and diagnostic confirmation was thus
US$ 26.19 million.
Assuming base case scenario (Table 2), the cost per new
diabetes case diagnosed was US$ 76 (Int$ 301). The cost
per diabetes case incorporated into healthcare, consider-
ing previously untreated individuals as well as newly diag-
nosed cases, was US$ 69 (Int$ 274).
In sensitivity analysis, varying the proportion of individu-
als with prior diabetes diagnosis participating in the
screening program did not impact significantly the esti-
mated number of new diabetes cases diagnosed. However,
varying the proportion of those fasting when screened
did, as the fasting cut point chosen (5.6 mmol/l), though
lacking in specificity, was more sensitive than the non-
fasting one (7.8 mmol/l); 32.7% of those fasting tested
positive, as opposed to only 8.9% of those having eaten in
the past 4 hours. If 50% of participants had been fasting
instead of 31%, using these cut points, the number
needed to screen to detect 1 case would have decreased
from 64 to 54.
Additionally, if a higher percentage of positive screenees
had returned for confirmation, higher screening effective-
ness would have been achieved, reaching 36 diabetes
cases diagnosed per 1,000 screened (if 100% had
returned). In this case, cost per diabetes case diagnosed
would decrease to US$ 53 (Int$ 212).
When considering additional local level costs, cost per
case detected increased proportionally, reaching US$ 80
(if 10%) and US$ 88 (if 25%). In the base case scenario,
we assumed that all positive screenees who returned for
confirmatory testing did so at the public health sector. If
25% or 75% of positive screenees had confirmed diagno-
sis with private providers, the cost per case detected would
increase 11% (US$ 84) and 33% (US$ 101), respectively.
Likewise, when labor cost estimates were considered as
50% higher than base case (reaching US$ 8.98 million),
cost per case detected increased to US$ 84. Considering
that it is unlikely that a professional with a bachelor or
higher degree would have been available for supervisory
activities in all 40,000 primary healthcare units in the
country, we estimated labor costs assuming such profes-
sionals were available in only 10,000 primary healthcare
units in the country. In such scenario estimated personnel
costs would be US$ 4.65 million and cost per case
detected increased to US$ 72.
Discussion
Principal findings
This massive population screening program conducted
via public healthcare clinics of Brazil, a large middle
income country, identified 3.4 million individuals as hav-
ing positive screening tests for diabetes. After diagnostic
confirmation, nearly 350,000 new cases of diabetes were
detected (one per 64 screened). Although the primary
objective of a screening program is to detect undiagnosed
cases of diabetes, some known cases of diabetes not previ-
ously receiving treatment were also incorporated through
the Campaign. Thus, a slightly larger number of cases
(one per 58 screened) were incorporated into the health
system. The cost per new case of diabetes diagnosed was
US$ 76.
Strengths of the study
Several features of the diabetes screening program con-
tributed to its success in terms of participation and yield,
and deserve comment. First, the screening was an integral
part of a major reorganization plan focusing on primary
healthcare services in which early detection of diabetes
was not an isolated objective. Since training primary care
providers was one of the plan's main activities, those whoBMC Health Services Research 2008, 8:189 http://www.biomedcentral.com/1472-6963/8/189
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conducted the screening were generally motivated. The
provision of diagnostic follow-up and care generally took
place at the site of screening.
Second, as diabetes awareness was an important aspect of
the plan, mass communication strategies were successful
in achieving a high participation rate [17].
Third, the Brazilian primary care network, like many in
low and middle income countries, has accumulated years
of experience in vaccination campaigns occurring in a
concentrated format over a short period of time. In this
setting, a "campaign approach" for diabetes detection was
seen by many as a natural extension of these preventive
activities.
Finally, positive screenees received a scaled recommenda-
tion to seek diagnostic confirmation, priority being given
to those with greater hyperglycemia. This avoided patient
overload during the initial months of the Campaign and
ensured that diagnosis and treatment would be provided
to those with greater probability of having diabetes. This
approach did, however, contribute to the low rate of con-
firmatory testing and thus a relatively low proportion of
confirmed diabetes among screen positives (See Addi-
tional file 1), especially among those in the lower range of
hyperglycemia.
Considering the need to improve quality of care for indi-
viduals with diabetes in Latin America [25], a significant
contribution of this program was its ability to use screen-
ing as a cornerstone of a larger plan aimed at reorganizing
the care of diabetes. The benefit of this approach is illus-
trated by the additional incorporation of approximately
60,000 cases of diabetes previously aware of their disease
yet apparently outside the reach of the health sector.
Although overall nationwide screening costs were signifi-
cant, the cost per new case of diabetes diagnosed was
lower than that observed in community screening strate-
gies reported in the literature, described as ranging from
US$ 100 to US$ 741 [26-30]. It should be noted, however,
that cross-national comparisons of program costs are dif-
ficult to interpret as these depend heavily on labor costs,
resource utilization, and other costs which are country
specific. Relative to developed countries reported high
labor cost, lower labor costs is likely to have influenced
the screening campaign total costs and cost per diagnosed
case in Brazil.
Implications
Screening for diabetes remains a controversial issue. Early
detection and treatment of diabetes logically allows for
early implementation of interventions proven to reduce
morbidity and mortality associated with diabetes and its
complications. Yet, universal screening for diabetes is not
recommended, mainly due to the lack of convincing evi-
dence that the benefits of early detection and treatment of
undiagnosed diabetes [11,31] justify the additional costs
incurred. Most guidelines recommend selective opportun-
istic screening [13,32] of patients seeking healthcare for
other reasons.
Undeniable gains in the organization of primary care
resulted from the inclusion of screening in the Brazilian
National Plan for the Reorganization of Diabetes Mellitus
and Hypertension Care. In so doing, millions were mobi-
lized across the country, thus demonstrably placing diabe-
tes on the agenda of primary care professionals. The
intangible nature of these gains and their associated costs
makes it difficult to contextualize the initial benefits and
costs of this unique effort with those of other reported
population-based screening efforts.
Several countries employ periodic public "campaigns" to
optimize prevention of infectious diseases through vacci-
nation. To date, similar public campaigns for chronic dis-
ease prevention, such as screening for diabetes, have not
been conducted and evaluated. This campaign approach
can, at relatively low cost, mobilize the population and
health system, suggesting its potential use in diabetes pre-
vention in selected settings.
One possibility, in this regard, would be to join diabetes
screening, or other chronic diseases prevention initiatives
with influenza vaccination campaigns.
Study limitations
Several limitations should be noted. The quality and legi-
bility of information recorded on screening forms filled
out by busy practitioners during the Campaign and the
exclusion of 2 of the 50 municipalities due to incomplete
records led to considerable missing information. The dif-
ficulty of locating addresses and frequent change of
address in less privileged settings in Brazil compounded
this problem. How this might have biased our findings is
not clear. If less privileged members of the community
were in fact more likely to be so excluded, our study may
underestimate true yield and thus overestimate true cost
per case, as these individuals would have been more likely
to have unknown diabetes, given inadequate pre-Cam-
paign access to health care. Additionally, information
regarding confirmatory testing and follow-up care were
based on self-reports given by screening participants dur-
ing interviews conducted one year later, rather than on
actual confirmatory testing, leading to inaccuracies.
Finally, as an oral glucose tolerance test was rarely used for
the diagnosis of diabetes in the clinical setting in Brazil in
2001, many cases of diabetes by isolated 2 h hyperglyc-
emia were missed by the Campaign.BMC Health Services Research 2008, 8:189 http://www.biomedcentral.com/1472-6963/8/189
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Conclusion
This nationwide population-based screening program,
conducted through primary care services, demonstrates
the feasibility, within the context of an organized national
healthcare system of a middle income country, of con-
ducting screening campaigns for chronic disease.
Although overall costs were significant, cost per new case
diagnosed was comparable or lower than those previously
reported. However, cost-effectiveness analysis and consid-
erations of the strategic value of a campaign approach are
necessary before recommending this form of screening for
other settings or for repeated use in Brazil.
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